m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG02694)
| Name |
Fenofibric acid
|
||||
|---|---|---|---|---|---|
| Synonyms |
Fenofibric acid; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; NSC 281318; Trilipix; alpha 1081; LF 178 acid; UNII-BGF9MN2HU1; LF 153; C17H15ClO4; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; NSC-281318; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; ABT-335; AK117112; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; FNF Acid; W-106287; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropionic acid; 2-[4-(4-Chloro-benzoyl)-phenoxy]-2-methyl-propionic acid (Fenofibric acid); ABT 335; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-; feno-fibric acid; Fibricor (TN); Fenofibrate free acid; FENOFIBRIC ACID; SCHEMBL16377; Fenofibrate related compound b; GTPL2662; ZINC1984; DTXSID8041030; BDBM28700; MQOBSOSZFYZQOK-UHFFFAOYSA-N; BCP22437; HY-B0760; KS-00000MR0; Fenofibric acid, analytical standard; LF-153; NSC281318; s4527; AKOS015889489; API0000561; 42017-89-0
Click to Show/Hide
|
||||
| Status |
Approved
|
||||
| Structure |
 |
||||
| Formula |
C17H15ClO4
|
||||
| InChI |
1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
|
||||
| InChIKey |
MQOBSOSZFYZQOK-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| INTEDE Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aldo-keto reductase 1C1 (AKR1C1)
YTH domain-containing family protein 1 (YTHDF1)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Fenofibric acid. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Fenofibric acid through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [2] | ||
References